Flu Vaccine for Influenza
Recruiting at 16 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: GlaxoSmithKline
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.
Are You a Good Fit for This Trial?
Adults aged 18 and above, both healthy individuals and those with stable chronic conditions, can join this flu vaccine study. They must be able to follow the trial's procedures, use contraception effectively, and have a BMI between 18-33 kg/m2. Pregnant women or those planning pregnancy are excluded.Inclusion Criteria
I have used reliable birth control for at least 4 weeks.
I agree to use birth control for 8 weeks after the study treatment.
I have taken a pregnancy test in the last 24 hours and it was negative.
See 6 more
What Are the Treatments Tested in This Trial?
Interventions
- Flu mRNA
Trial Overview The trial is testing different formulations of GSK's mRNA-based flu vaccines (Formulation A, B1, B3) against comparators in younger and older adults to evaluate immune response and safety.
How Is the Trial Designed?
10Treatment groups
Experimental Treatment
Active Control
Group I: Flu mRNA_4_YAExperimental Treatment1 Intervention
Eligible YA participants receive a single dose of Flu mRNA Formulation A (GSK6479720A) as study intervention at Day 1.
Group II: Flu mRNA_4_OAExperimental Treatment1 Intervention
Eligible YA participants receive a single dose of Flu mRNA Formulation A (GSK6479720A) as study intervention at Day 1.
Group III: Flu mRNA_3_YAExperimental Treatment1 Intervention
Eligible YA participants receive a single dose of Flu mRNA Formulation B3 (GSK6498032A) as study intervention at Day 1.
Group IV: Flu mRNA_3_OAExperimental Treatment1 Intervention
Eligible YA participants receive a single dose of Flu mRNA Formulation B3 (GSK6498032A) as study intervention at Day 1.
Group V: Flu mRNA_1_YAExperimental Treatment1 Intervention
Eligible Younger Adults (YA) participants receive a single dose of Flu mRNA Formulation B1 (GSK6498032A) as study intervention at Day 1.
Group VI: Flu mRNA_1_OAExperimental Treatment1 Intervention
Eligible Older Adults (OA) participants receive a single dose of Flu mRNA Formulation B1 (GSK6498032A) as study intervention at Day 1.
Group VII: Comparator_1_OAExperimental Treatment1 Intervention
Eligible OA participants receive a single dose of comparator 1 at Day 1.
Group VIII: Comparator_1_YAActive Control1 Intervention
Eligible YA participants receive a single dose of comparator 1 at Day 1.
Group IX: Comparator_2_YAActive Control1 Intervention
Eligible YA participants receive a single dose of comparator 2 at Day 1.
Group X: Comparator_2_OAActive Control1 Intervention
Eligible OA participants receive a single dose of comparator 3 at Day 1.
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.